

# Candriam Impact One

Quarterly Report

# Investor letter

Dear investors,

2022 is starting successfully with our investment in Ananda, a German Impact fund. Candriam Impact one is now invested in 6 participations which brings our total commitment to 62.7%, of which we have already called 12.1%. With this new commitment, Impact One increases its investment in climate-related topics such as waste management, resource scarcity and solutions to reduce CO2 emissions. Our thematic diversification is as follows: 36% well-being, 20% basic needs, 10% decent work, 16% resource scarcity, 14% climate stability, 4% healthy ecosystems. 32% of the fund is invested in VC and 31% in Growth and Buyout. Our impact result represents so far a performance of 3.83%.

Our underlying participations are extremely active with a total of 41 companies supported by Impact One. As we speak all our GP's are closed to new investments with committed capital that exceeded their initial targets:

**Ananda Impact Fund IV** final closing took place on March 31 2022, with a total committed capital of EUR 109.4 million. Ananda is already engaged in two companies for a total of 6.6 million that will be included in the June reporting.

**Impact Growth IV** has closed the subscription period to new investments with a total of 151.8 million. As of March 2022 the total amount called was 36 million. Impact Growth IV is extremely active in deal analysis with more than 41 opportunities that have reached a pre-study stage across Europe. During the quarter Impact Partners realized an investment in Velogik. Impact Partners IV has already invested in 12 European companies since its launch with an already successful impact result of 17.1%.

**Sofinnova Industrial Biotech II** has closed its subscription period on March 1st 2022 with a total committed capital of Eur 175 million significantly above the 125 million target. As of March 2022, 15% of the fund committed capital was paid-up. During the quarter the fund completed two new investments for a total amount of 5.8 million: GF Biochemicals, founded in 2008 in Italy, with its head quarter in France. GFBiochemical produces Levulinic acid derivatives at commercial scale directly from biomass. Sofinnova committed Eur 7.5 million as lead investor in a 15 million series A financing. The second company is Prometheus Materials, based in the US. Prometheus is a biomaterial company focusing on the production of biological concrete with the objective to replace highly CO2 emitting cement-based concrete production. The fund committed 5 million as lead investor in a 8 million series A financing. As of March 31st Sofinnova comprises of 4 companies plus one seed pool investment for a total of 8.2% of the fund.

**Yotta Smart Industry Fund** focuses on the development of French industry 4.0 SMEs with a 25% CO2 reduction target at the portfolio level. The industrial footprint is increasingly becoming a fundamental path. During the quarter Eldim joined Yotta's portfolio. Eldim is a French leader in optical device control, a fast growing market for virtual and augmented reality applications and the penetration of laser diodes in automotive for example. This transaction brings Yotta's total number of companies to 6. All portfolio's companies are benefitting from dynamic demand and current global events have accelerated awareness of the economic changes toward less fossil-fuel and increasingly more digital goods and services. To define carbon footprint reduction roadmap, Yotta focuses on the environmental quality of purchasing and inbound and outbound freight which accounts for a large portion of carbon emissions in these companies. However despite strong margin results in 2021, 2022 supply-side crisis and returning inflation may be a challenge to consider.

**Lauxera Growth I S.L.P.**'s investment team had a busy quarter executing a majority investment in Matrix Requirements and signing a bidding offer to invest in a Medtech innovation service. Details on these deals will be shared in our next reporting with their final closing. Healthcare and Healthtech sectors show a relative decoupling to the fundamental macro environment background. January started strong, at nearly 3x the pace of 2021 leading to a Q1 2022 total healthtech funding in Europe of more than 1.8x the quarterly average from 2021. February and March are slowing down. Lauxera is approaching the market carefully given valuations that are remaining very high. For instance they passed on a growth deal in bio production that went to NBO at a valuation more than 50% over what they were willing to pay. Their deal flow and pipeline remain very rich. They screened 221 deals in Q1 and engaged in 4 full due diligences signing 1 bidding offer.

**Rubio Impact Fund II** focusing on circular economy invested 15.5 million in 14 social enterprises to date. The latest one is Vytal that deploys re-usable containers for take-away food replacing the single-use packaging. After 1.5 year into the fund, 2 early stage companies are struggling. Litterati that maps litter globally, and 30Mhz, a plug & play data platform to improve farming practices and reduce the use of resources. Gas price development has made customers reluctant to invest in experimental solutions for the moment. On the other side two early stage companies Taylor (solar panel efficiency hardware) and DeWarmte (heatpumps using sewage water as heat source) have launched their products with hundred of customers using their technology to cut energy costs and emissions. Novameat (alternative protein meat) and Arborea (industrial algae production technology) both raised multi-million EU subsidies and are building their first production equipments. Wakuli (home delivered coffee subscription) raised money at 3x Rubio initial valuation. Incision (GoogleMaps for surgery to reduce complication) is raising additional capital to help grow their new products. So overall Rubio is inline with our expectations.

Regarding deal flow, we are in an active due diligence with an Energy transition French fund that will focus on electrification, asset sharing, hydrogen and retrofitting. The fund focuses on growth capital. We see record amounts raised and deployed in "Impact" venture funds while public market are slowing. We hence remain very cautious when analyzing our growing pipeline.

We are remaining very active in discussing with potential LP's despite the closing date of Candriam Impact One approaching and remain confident in growing our LP base in the close future. We are proud to announce the commitment of a very recognized institutional investor in our fund bringing our total AUM to EUR 32m.

We hope you are all safe,  
Sincerely,  
Impact One Team



> **FUND**

> PORTFOLIO

> NEW PORTFOLIO COMPANIES

# Fund details

<b>Name</b>	Candriam Impact One
<b>Legal form</b>	FPCI
<b>Fund's domicile</b>	France
<b>Financial year-end of the Fund</b>	31 December
<b>Fund base currency</b>	EUR
<b>Investment Manager</b>	Candriam France 40 rue Washington F-75408 Paris Cedex 08 France
<b>AMF Registration #</b>	GP03007
<b>Commitment Amount</b>	EUR 26 000 000
<b>A Shares subscribed (EUR 1 000 / share)</b>	26 000 A shares
<b>B Shares subscribed (EUR 1 000 / share)</b>	0 B shares
<b>First closing:</b>	25/05/2020
<b>Vintage year (Date of 1st capital call):</b>	2020
<b>Subscription period</b>	1 year + 6 months + 6 months
<b>Maturity</b>	12 years
<b>End of investment period</b>	25 May 2024
<b>Management Fees</b>	0.50%
<b>Financial Hurdle</b>	3%
<b>Impact Hurdle</b>	50%

# Fund indicators as at March 31<sup>st</sup> 2022

<b>Total committed capital</b>		EUR 26,000,000
<b>GP commitment</b>	0.5% of total committed capital at final closing	
<b>Contributed capital</b>		EUR 3,500,000
<b>History of contributions</b>	15 June 2020	EUR 500 000
	19 January 2021	EUR 500 000
	26 February 2021	EUR 500 000
	1 June 2021	EUR 500 000
	28 July 2021	EUR 500 000
	August 25 2021	EUR 500 000
	October 27 2021	EUR 500 000
<b>Net Assets</b>		EUR 2,700,692
<b>Net Assets + Callable Capital</b>		EUR 25,200,692
<b>Invested Amount + Callable Capital</b>		EUR 25,641,954
<b>Portfolio (cost of all acquisitions)</b>		EUR 3,141,954
<b>Portfolio (at valuation, including exits)</b>		EUR 2,521,634
<b>Distributed Capital</b>		EUR 0
<b>History of distributions to LPs</b>		EUR 0
<b>History of distributions to GPs</b>		EUR 0
<b>% of Fund invested since inception:</b>		12.1%
<b>% of contributed capital distributed to LPs</b>		0.0%
<b>Ratios</b>		
<i>Distributions / Contributed Capital</i>		0.0%
<i>Net Asset / Contributed Called</i>		77.2%
<i>(Distributions + Net Asset) / Contributed Capital</i>		77.2%
<i>Distributions / Total Committed Capital</i>		0.0%

# A shares since fund inception as at March 31<sup>st</sup>, 2022

<b>A share inception Value</b>	EUR 1,000.00
<b>Contributed Capital</b>	EUR 134.62
<b>Distributed Capital</b>	-
<b>Management Fees</b>	EUR 2.92
<b>Other Charges</b>	EUR 12.23
<b>Allocation to Carried Interest</b>	-
<b>A share Net Asset Value</b>	EUR 103.87
<b>Callable Distributed Capital</b>	EUR 0.00
<b>Uncalled Capital</b>	EUR 0.00

# Other Financial Information

---

## Fees and New Provisions for Q1-2022

<b>Management fees</b>	EUR 10,345
<b>CACEIS fees</b>	EUR 10,934
<b>Audit fees</b>	EUR 1,726
<b>Transaction fees</b>	EUR 0
<b>Legal fees</b>	EUR 0
<b>Organisational expenses</b>	EUR 0
<b>Others</b>	EUR 0

# Fund Activity during Q1-2022

---

## ■ Capital Calls Sent

- ▶ Over the quarter, no capital call was sent to LPs

## ■ Capital Calls Received

- ▶ Over the quarter, 2 capital calls were received from:
  - 1x Rubio Impact Fund II Coöperatie U.A    EUR    45 000
  - 1x Yotta Smart Industry Fund                    EUR    130 000



# Fund Activity during Q1-2022

---

## ■ Commitments

- ▶ One new commitment was signed during Q1-2022 in Ananda Impact Fund IV. The fund was presented to the fund's Impact Committee on January 27<sup>th</sup>.

## ■ Distribution

- ▶ N/A

## ■ Research

- ▶ Over the course of Q1, the team has been actively working on closing the deal with Ananda as well as on starting a due diligence on a new France based Impact Fund with a focus on Energy Transition.



> FUND

> **PORTFOLIO**

> NEW PORTFOLIO COMPANIES

# Residual portfolio valuation as of March 31<sup>st</sup>

Investment		Commitment					Investment Status					
Position	Country	Date	Amount (EUR)	%TCC	%Membership	%Called	Cost	Valuation	Distribution	PnL	Multiple	
1	Rubio Impact Fund II Coöperatie U.A	Netherlands	23/11/2020	2,500,000	9.62%	2.5%	19.0%	473,954	391,612	-	- 82,342	0.83x
2	Impact Croissance IV	France	17/11/2020	3,400,000	13.08%	2.2%	18.4%	626,600	502,211	-	- 124,389	0.80x
3	Lauxera Growth I S.L.P.	France	04/01/2021	2,000,000	7.69%	0.8%	39.3%	786,000	509,824	226,000	- 50,176	0.94x
4	Sofinnova Industrial Biotech II	France	12/02/2021	3,100,000	11.92%	2.0%	15.0%	465,000	407,686	-	- 57,314	0.88x
5	Yotta Smart Industry Fund	France	18/06/2021	2,600,000	10.00%	2.0%	30.4%	790,400	710,301	-	- 80,099	0.90x
6	Ananda Impact Fund IV	Germany	31/03/2022	2,700,000	10.38%	2.5%	0.0%	-	-	-	-	N/A
<b>Total</b>				<b>16,300,000</b>	<b>62.7%</b>		<b>12.1%</b>	<b>3,141,954</b>	<b>2,521,634</b>	<b>226,000</b>	<b>- 394,320</b>	

Net Unrealised Gain (Loss) on portfolio Investments **-EUR 394,320**

# Portfolio 1/2

Fund	Company	Investment	% Ownership	Multiple	Impact performance
Rubio Impact Fund II					
1	Wakuli	EUR 1,850,000	24.50%	3.1x	1%
2	Mosa Meat BV	EUR 1,500,000	0.80%	1x	0%
3	Skillab BV	EUR 1,500,000	N/A	1x	1%
4	Incision	EUR 2,000,000	10.60%	1.1x	17%
5	Litterati	EUR 493,000	N/A	1x	30%
6	Arborea	EUR 702,000	5.60%	1x	0%
7	Taylor	EUR 1,500,000	21.70%	1x	0%
8	30MHz	EUR 1,458,000	13.10%	1x	14%
9	Lingvist	EUR 2,500,000	10%	1x	0%
10	DeWarmte	EUR 800,000	22.90%	1x	0%
11	Microverse	EUR 433,957	1%	1x	2%
12	Winc Academy	EUR 1,108,450	10.10%	1x	0%
13	Novameat	EUR 1,250,000	5%	1x	0%
14	Vytal	EUR 1,800,000	5.80%	1x	9%

Fund	Company	Investment	% ownership	Multiple	Impact performance
Impact Croissance IV					
1	Mi Cuento	EUR 1,899,998	18.91%	0.1x	21%
2	Choose my Company (CMC)	EUR 1,782,906	21.30%	1.24x	19%
3	Dans ma Culotte	EUR 2,730,120	33.84%	0.26x	19%
4	Percko	EUR 3,002,896	18.68%	1.1x	8%
5	Okeenea	EUR 3,000,000	45.20%	1.01x	31%
6	Neuronation	EUR 2,737,767	28.01%	1.18x	12%
7	Wefight	EUR 1,615,281	9.76%	1x	42%
8	360 Medical	EUR 2,572,421	8.14%	1x	14%
9	Top Doctors Holding	EUR 3,885,012	8.68%	1x	18%
10	Chromaviso Holding	EUR 2,254,870	23.48%	0.9x	0%
11	Abogados	EUR 1,045,311	29.68%	1x	11%
12	Velogik	EUR 2,001,825	16.68%	1x	0%

# Portfolio 2/2

Fund	Company	Investment	% ownership	Multiple	Impact performance
Lauxera Growth I S.L.P.					
1	Caresyntax Corporation	EUR 8,240,000	3.00%	1.09x	26%
2	Lumicks	EUR 12,570,000	5.00%	1.08x	7%
3	PSIH	EUR 23,950,000	61.0%	1.01x	33%
4	Lifen	EUR 18,950,000	7.00%	1x	0%
5	Reapplix	EUR 3,100,000	6.9%	1x	0%
6	Matrix Requirements	EUR 10,000	N/A	1x	0%

Fund	Company	Investment	% ownership	Multiple	Impact performance
Sofinnova Industrial Biotech II					
1	Meiogenix	EUR 1,999,866	17.70%	1x	0%
2	Elicit Plant SAS	EUR 5,999,992	26.00%	1x	0%
3	GF Biochemicals	EUR 3,500,000	11.30%	1x	0%
4	Prometheus	EUR 2,273,466	12.00%	1x	0%

Fund	Company	Investment	% Ownership	Multiple	Impact performance
Yotta					
1	Groupe R&D / Folan	EUR 4,500,000	10.5%	1x	0%
2	AET Technologies	EUR 6,200,000	44%	1x	0%
3	DBC	EUR 4,500,000	44%	1x	0%
4	RECIF	EUR 8,608,000	67%	1x	0%
5	Eldim	EUR 5,500,000	18%	1x	0%



> FUND


> PORTFOLIO

> **NEW PORTFOLIO COMPANIES**

# Portfolio companies

Company	<b>Name</b>	Vytaal	<b>The Impact problem</b>	Production, transport and waste of single-use packaging leads to significant material footprint (water, fossil fuels...) and carbon footprint (emissions from production and transport).
	<b>Business</b>	Vytaal aims to reduce single-use packaging for food delivery with a reusable packaging solution. Vytaal's proprietary technology enables the company to efficiently track containers and manage inventory since each container is linked to a restaurant or a user account.	<b>SDG</b>	
	<b>Theme</b>	Circular solutions	<b>Impact Goals</b>	<b>KPI 1</b> Single-use packages avoided
	<b>Location</b>	Cologne, Germany		<b>KPI 2</b> Average days for a reusable container to return
	<b>Inception</b>	2020		
<b>Exit perspective</b>	No consideration.			
Investment	<b>Date of investment</b>	March 2022	<b>% Impact Achieved</b>	
	<b>Type</b>	NA		
	<b>Amount invested</b>	EUR 1.8 million		
	<b>Commitment</b>	EUR 1.8 million		
	<b>% ownership</b>	5.8%		
Financial	<b>Enterprise value</b>	N/A		
	<b>Revenue</b>	N/A		
	<b>EBITDA</b>	N/A		

# Portfolio companies

Company	<b>Name</b>	Lifen	<b>The Impact problem</b>	Supporting public hospitals in steering core activities, reducing costs and improving control functions. The biggest pain point in Healthtech is rolling out new digital health software
	<b>Business</b>	Software company that develops and commercializes widely-used applications and interoperability solutions for healthcare institutions and healthcare professionals (HCP's).	<b>SDG</b>	
	<b>Theme</b>	Healthcare digitization	<b>Impact Goals</b>	<b>KPI 1</b> Time saved for HCP's
	<b>Location</b>	Paris		<b>KP 2</b> Amount saved for hospitals through digitalization of documents exchange
	<b>Inception</b>	2016		
<b>Exit perspective</b>	Trade sale to PE or strategic			
Investment	<b>Date of investment</b>	October 2021	<b>% Impact Achieved</b>	
	<b>Type</b>	Growth		
	<b>Amount invested</b>	EUR 16 million		
	<b>Commitment</b>	EUR 16 million		
	<b>% ownership</b>	7%		
Financial	<b>Pre-money</b>	EUR 143 million		
	<b>Revenue</b>	EUR 9 million		
	<b>Gross profit</b>	EUR 4 million		



# Portfolio companies

## Company

**Name** Elicit Plant

**Business** Development of a biobased and scalable solution to stimulate the metabolism of plants so that they reduce their water consumption and are less sensitive to water stress. This enable plants to improve resistance to drought.

### The Impact problem

Drought is particularly damaging to agriculture as it causes more loss in crop yield each year than all pathogens combined. This is a growing concern due to climate change. For example areas under drought conditions have more than doubled in the last 30 years.

### SDG



**Theme** Industrial Biotech

**Location** Moulins sur Tardoire, France

**Inception** 2018

**Exit perspective** Mixed, Industry acquisition

### Impact Goals

- KPI 1** Satisfactory proof of efficacy of use of Elicit drought management products: increase yield by at least 10% compared to untreated field. Weight: 50%
- KPI 2** Surface treated with Elicit products reaches of 4000 ha in 2022, 44000 ha in 2023 and 143000 ha in 2024. Weight 50%

## Investment

**Date of investment** October 2021

**Type** Serie A lead

**Amount invested** EUR 6 million

**Commitment** EUR 6 million

**% ownership** 26%

### % Impact Achieved

## Financial

**Pre-money** EUR 15.8 million

**Net Sales** N/A

**Gross profit** N/A

# Portfolio companies



## Company

**Name** GF Biochemicals

**Business** GF develops sustainable production of bio-solvents and bio-plasticizers for industrial applications in order to reduce CO2 emissions as well as the dependence on oil-based products. The Levulinic acid is a highly flexible biobased molecule to manufacture industrial and specialty chemicals.

### The Impact problem

Solvents are a type of organic chemical that evaporate readily, releasing harmful emissions. Solvents are used in the day-to-day operations of many businesses such as paints and coatings, printing inks, cleaning products, pharmaceuticals, cosmetics which need to reduce their conventional solvents usage.

### SDG



**Theme** Biochemicals: Production of biobased levulinic acid and derivatives

### Impact Goals

**Location** Paris

**Inception** 2008

**Exit perspective** IPO or strategic acquisition

- KPI 1** For 2 solvents at commercial scale level, demonstrate at least a 70% reduction of overall CO2 production. Weight: 60%
- KPI 2** Substitute in HPC or paints and coatings 2 high concern substances by year 4. Weight: 20%
- KPI 3** Achieved 10 recurring customers and 750 tpa of sales volume in year 3. Weight: 20%

## Investment

**Date of investment** September 2021

**Type** Serie A lead

**Amount invested** EUR 7.5 million

**Commitment** EUR 15 million

**% ownership** 11.3%

### % Impact Achieved

## Financial

**Pre-money** EUR 20 million

**Net Sales** N/A

**Gross profit** N/A

# Portfolio companies



## Company

<b>Name</b>	Prometheus	<b>The Impact problem</b>
<b>Business</b>	Prometheus is a biomaterials biotech company with solutions focusing on precast building products to replace energy intensive carbon emitting industrial materials. The company leverages marine organisms to develop new ways of producing concrete without any CO2 emissions.	<b>SDG</b>
<b>Theme</b>	Biomaterials-Production of biological concrete	
<b>Location</b>	Boulder, Colorado	<b>Impact Goals</b>
<b>Inception</b>	2021	
<b>Exit perspective</b>	Mixed, Industry acquisition	

Concrete is the most widely used material on our planet. The production of cement , key ingredient in concrete is responsible for 9% of global CO2 emissions. The challenge of lowering these emissions is key to humankind today.



## Investment

<b>Date of investment</b>	February 2022	<b>% Impact Achieved</b>
<b>Type</b>	Serie A lead	
<b>Amount invested</b>	EUR 2.2 million	
<b>Commitment</b>	EUR 4.4 million	
<b>% ownership</b>	12%	

- KPI 1** Proof of reduction of overall CO2 in concrete production of at least 50% reduction in 2 years and 75% by the end of year 3. Weight: 70%
- KPI 2** Ability to produce internally or through sales 750,000 CMUs no later than year 4. Weight: 20%
- KPI 3** Reach and maintain a "Living Building Challenge Red List" free chemical commitment before end of year 3. Weight:10%

## Financial

<b>Pre-money</b>	EUR 15 million
<b>Net Sales</b>	N/A
<b>Gross profit</b>	N/A

# Portfolio companies



Company	<b>Name</b>	Eldim	<b>The Impact problem</b>	Carbon footprint is largely dependent on purchasing (Scope3 downstream, 55% of carbon footprint)
	<b>Business</b>	Designs, manufactures and sells optical metrology equipment dedicated to measurement and control displays. It also develops devices dedicated to quality control of 3D sensors used in facial recognition or in autonomous driving.	<b>SDG</b>	
	<b>Theme</b>	Optical components and metrology equipment		
	<b>Location</b>	Normandie, France	<b>Impact Goals</b>	
	<b>Inception</b>	1992		<b>KPI 1</b> Reduce carbon emissions by 25%
	<b>Exit perspective</b>	N/A		
Investment	<b>Date of investment</b>	March 2022		
	<b>Type</b>	Growth, minority stake	<b>% Impact Achieved</b>	
	<b>Amount invested</b>	EUR 5.5million		
	<b>Commitment</b>	EUR 5.5 million		
	<b>% ownership</b>	17.9%		
Financial	<b>Enterprise Value</b>	EUR 33.6 million		
	<b>EBITDA</b>	EUR 2.26 million		
	<b>Sales</b>	EUR 9.9 million		



# SDG Mapping


UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance	
1 NO POVERTY	SDG 1: NO POVERTY	Financial inclusion	Number of farmers sourced from in the last 12 months	-	Wakuli	100			1%
		Access to basic goods and services	Number of schools reached by awareness campaigns	2096	Dans Ma Culotte	11	1%	0%	10%
		Underserved communities	Cumulative number of clients at risk of poverty who had their debt reduced through the services of Abogados	1798	Abogados	48	3%	1%	11%
		Underserved communities	Cumulative amount of debt cancelled for the customers of 1st KPI (in m EUR)	14.39	Abogados	3	20%	10%	
2 ZERO HUNGER	SDG 2: ZERO HUNGER	Sustainable agriculture	Technology Readiness Level (TRL) # achieved	-	Arborea	-			0%
		Sustainable agriculture	Environmental footprint in CO2 equivalent emissions/kg	-	Arborea	-			
		Sustainable agriculture	Number of high tech customers	-	30MHz	37			3%
3 GOOD HEALTH AND WELL-BEING	SDG 3: GOOD HEALTH AND WELL-BEING	Sustainable agriculture	Number of mid/low tech customers	-	30MHz	30			
		Fitness and wellbeing	Number of blue collar equipped with protective vest	230,000	Percko	18,000	8%	4%	8%
		Reproductive health	Years of hygienic protection available to poor women through foundations / universities	99,000	Dans Ma Culotte	18,932	19%	10%	
		Ageing	Number of people over 50+ with identified dementia risk trained (prevention)	7,368	Neuronation	0	0%	0%	12%
		Ageing	Number of patients in a healthcare process (treatment)	45,300	Neuronation	17,236	38%	19%	
		Biotechnology	Inclusions of data in investigational new drug application	20	Lumicks	0	0%	0%	7%
		Biotechnology	Number of scientific publication	561	Lumicks	84	15%	7%	
		Biotechnology	Reduction in surgical site infections/per year	13,000	Caresyntax	1,600	12%	4%	26%
		Access to healthcare	Time saved/day/op. room	16	Caresyntax	5	31%	10%	
		Access to healthcare	Reduction in or consumables utilization and cost	73	Caresyntax	25	34%	11%	
		Access to healthcare	Number of reductions in surgical complications	TBD	Incision	7,000			17%
		Access to healthcare	Cumulative number of patients accompanied in their treatment in oncology	39,030	Wefight	4,390	11%	6%	42%
		Access to healthcare	Cumulative number of patients referred to a doctor specialist	7,320	Wefight	5,296	72%	36%	
		Access to healthcare	Number of doctors registered on the platform in Medical Deserts	19,000	360 Medical	3,021	16%	8%	14%
		Access to healthcare	Number of in-app openings, intended for medical specialists, by general practitioners	322,103	360Medical	40,514	13%	6%	
		Access to healthcare	Cumulative number of appointments made by patients based in deserts medical	537,280	Top Doctors Holding	101,792	19%	9%	18%
		Access to healthcare	Cumulative number of appointments performed by patients without private insurance	829,946	Top Doctors Holding	142,573	17%	9%	
Access to healthcare	Time saved/month/active user	3	PSIH	2	67%	33%	33%		
Access to healthcare	Number of elderly in retirement homes with circadian lights	247	Chromaviso	0	0%	0%	0%		
Access to healthcare	Number of beds in hospitals and psychiatric wards equipped with circadian lights	5,239	Chromaviso	0	0%	0%			
Access to healthcare	Time saved for HCPs		Lifen	2			0%		
Access to healthcare	Amount saved for HS through digitalization or doc exchange (KE)		Lifen	0			0%		
Access to healthcare	Number of amputations prevented		Reapplix	14			0%		
Access to healthcare	Number of DFUs healed		Reapplix	54			0%		
Access to healthcare	Savings to the Health system (K\$)		Reapplix	743			0%		

# SDG Mapping

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
4 QUALITY EDUCATION	SDG 4: QUALITY EDUCATION	Access to education	Number of books sold adapted to reading disabilities	M Cuento	2,117	2%	1%	21%
		Access to education	Number of new titles in adapted format	M Cuento	56	40%	20%	
		Access to education	Relevant language learning users	Lingvist	-			0%
		Access to education	Number of graduates who have found an international job above income threshold of USD 1,000 per month	Microverse	100			2%
		Access to education	Cumulative number of students who completed a skills course at Winc Academy	Winc Academy	350			0%
7 AFFORDABLE AND CLEAN ENERGY	SDG 7: AFFORDABLE AND CLEAN ENERGY	Energy efficiency	Kiloton CO2 emissions avoided	Taylor	360			0%
		Energy efficiency	Tons CO2 emissions avoided	DeWarme	2			0%
8 DECENT WORK AND ECONOMIC GROWTH	SDG 8: DECENT WORK AND ECONOMIC GROWTH	Developed world jobs	Cumulative number of completed skill profiles	SkillLab	1,500			1%
		Developed world jobs	Number of nurses equipped with protective clothing	Percko	2,500	8%	4%	
		Developed world jobs	Number of respondents being apprentices or blue collar	Choose My Company	35,000	28%	14%	19%
		Developed world jobs	Number of companies certified IMPACTINDEX	Choose My Company	36	9%	5%	
		Developed world jobs	Number of people hired through inclusion networks	Velogik	0	0%	0%	0%
9 INDUSTRY, INNOVATION AND INFRASTRUCTURE	SDG 9: INDUSTRY, INNOVATION AND INFRASTRUCTURE	Developed world jobs	Number of FTEs that Velogik allows to create or to feed in insertion structures	Velogik	0	0%	0%	0%
		Sustainable physical infrastructure	Substitute in HPC or paints and coatings 2 high concern substances by year 4	GF Biochemicals				0%
11 SUSTAINABLE CITIES AND COMMUNITIES	SDG 11: SUSTAINABLE CITIES AND COMMUNITIES	Sustainable physical infrastructure	Ability to produce internally or through sales 750,000 CMUs no later than year 4	Prometheus				0%
		Smart cities and mobility	Number of public facilities being accessible	Okeenea	1,280	37%	18%	31%
12 RESPONSIBLE CONSUMPTION AND PRODUCTION	SDG 12: RESPONSIBLE CONSUMPTION AND PRODUCTION	Smart cities and mobility	Number of audio-signal devices implemented in traffic lights	Okeenea	25,200	25%	13%	
		Resource efficiency	Regulatory approval of the product	Mosa Meat	0			0%
		Resource efficiency	Cost reduction in cultured meat (in %)	Mosa Meat	0			
		Resource efficiency	50% increase in targeted recombination events in relevant commercial specie due to the MeioGenix Technology	MeioGenix	0			0%
		Resource efficiency	3-fold increase in targeted meiotic recombination using MeioGenix Technology in any crop species in at least one cold recombination genomic location	MeioGenix	0			
		Resource efficiency	Recovery of a commercially relevant plant carrying a disease resistant trait devoid of the genetically linked negative agronomy using MeioGenix Technology	MeioGenix	0			
		Resource efficiency	Pieces of litter registered	Litterati	16800			30%
		Resource efficiency	Number of stories of impact	Litterati	5000			
		Resource efficiency	Satisfactory proof of efficacy of use of Elicit drought management products: increase yield by at least 10% compared to untreated field.	Elicit Plant				0%
		Resource efficiency	Surface treated with Elicit products reaches of 4000 ha in 2022, 44000 ha in 2023 and 143000 ha in 2024	Elicit Plant				0%
		Resource efficiency	Progress in bringing lab technology to production at scale	Novameat	0			0%
		Resource efficiency	Single-use packages avoided	Vital	267000			9%
		Resource efficiency	Average days for a reusable container to return	Vital	28			0%
13 CLIMATE ACTION	SDG 13: CLIMATE ACTION	Environmental health	Achieved 10 recurring customers and 750 tpa of sales volume in year 3	GF Biochemicals				0%
		Environmental health	Reach and maintain a "Living Building Challenge Red List" free chemical commitment before end of year 3	Prometheus				0%
		Greenhouse gas reduction	Reduce carbon emissions by 25%	Folan	0			0%
		Greenhouse gas reduction	Reduce carbon emissions by 25%	AET Group	0			0%
		Greenhouse gas reduction	Reduce carbon emissions by 25%	DBC	0			0%
		Greenhouse gas reduction	Reduce carbon emissions by 25%	Eldim	0			0%
		Greenhouse gas reduction	Reduce carbon emissions by 25%	RECIF	0			0%
		Greenhouse gas reduction	For 2 solvents at commercial scale level, demonstrate a 70% reduction of CO2 production. Weight: 60%	GF Biochemicals				0%
		Greenhouse gas reduction	Proof of reduction of overall CO2 in concrete production of at least 50% reduction in 2 years and 75% by the end of year 3	Prometheus				0%
		Greenhouse gas reduction	Metric tons produced of approved cultured beef	Mosa Meat	0			
15 LIFE ON LAND	SDG 15: LIFE ON LAND	Healthy ecosystems	Tons of meat analogues sold by Novameat	Novameat	0		0%	


# Portfolio Breakdown

Impact Themes Breakdown




- Basic Needs
- Decent Work
- Resource Scarcity
- Climate Stability
- Healthy Ecosystems
- Wellbeing

Geographical Breakdown



- Netherlands
- Spain
- France
- United States
- Germany
- Estonia
- Denmark
- United Kingdom

SDG Breakdown



- SDG 1 : No Poverty
- SDG 2 : Zero Hunger
- SDG 3 : Good Health and Wellbeing
- SDG 4 : Quality Education
- SDG 7 : Affordable and clean energy
- SDG 8 : Decent Work and Economic Growth
- SDG 9 : Industry, Innovation and Infrastructure
- SDG 11 : Sustainable Cities and Communities
- SDG 12 : Responsible Consumption and Production
- SDG 13 : Climate Action
- SDG 15 : Life On Land

This document is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performances of a given financial instrument or index or an investment service or strategy, or simulations of past performances, or forecasts of future performances are not reliable indicators of future performances and are not guaranteed.

Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

Candriam consistently recommends investors to consult via our website [www.candriam.com](http://www.candriam.com) the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. This information is available either in English or in local languages for each country where the fund's marketing is approved.





CLIENT RELATION  
OFFICES

---

- AMSTERDAM
- DUBAI
- FRANKFURT
- GENEVA
- ZURICH
- MADRID
- MILAN
- NEW YORK

MANAGEMENT  
CENTERS

---

- LUXEMBOURG
- BRUSSELS
- PARIS
- LONDON